Latest news
How Psoriatic Arthritis Trial Success and Q2 Losses Could Shape MoonLake Immunotherapeutics (MLTX) Investors - simplywall.stsimplywall.st · Mon, 10 Aug 2026 22:33:35 GMTMoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial - Fierce BiotechFierce Biotech · Mon, 10 Aug 2026 15:00:26 GMTSonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial - Dermatology TimesDermatology Times · Mon, 10 Aug 2026 14:00:21 GMTMoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’ - StocktwitsStocktwits · Mon, 10 Aug 2026 13:24:00 GMTSetting the Stage: The Burden of Psoriatic Arthritis and the Treatment Landscape - Managed Healthcare ExecutiveManaged Healthcare Executive · Mon, 10 Aug 2026 12:07:51 GMTPerspectives on Psoriatic Arthritis - Everyday HealthEveryday Health · Thu, 06 Aug 2026 22:36:57 GMTConsistent Safety Profile of Risankizumab Across Psoriasis and Psoriatic Arthritis - HCPLiveHCPLive · Thu, 06 Aug 2026 12:05:44 GMTA Clinical Framework for Assessing & Managing Cardiovascular Risk in Psoriatic Arthritis - Physician's WeeklyPhysician's Weekly · Sun, 02 Aug 2026 20:45:31 GMT